Improvement of TGF-β1 signaling may be a novel therapeutic approach to AD, simultaneously targeting a neurodegenerative pathway and preventing Aβ deposition (Caraci et al., 2012). The gene discussed is TGFB1; the disease is Alzheimer disease.